Polymyositis and dermatomyositis laboratory findings: Difference between revisions
Jump to navigation
Jump to search
Line 24: | Line 24: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Frequency | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Frequency | ||
|- | |- | ||
| rowspan=" | | rowspan="9" align="left" style="background:#F5F5F5;" + |Antisynthetase | ||
| align="left" style="background:#F5F5F5;" + |Anti-Jo-1 | | align="left" style="background:#F5F5F5;" + |Anti-Jo-1 | ||
| align="left" style="background:#F5F5F5;" + |Histidyl-tRNA synthetase | | align="left" style="background:#F5F5F5;" + |Histidyl-tRNA synthetase | ||
Line 44: | Line 44: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Myositis, mechanic's hands, Gottron's papules, arthritis | * Myositis, mechanic's hands, Gottron's papules, arthritis | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + |5-10% | ||
|- | |- | ||
| rowspan="2" align="left" style="background:#F5F5F5;" + |Anti PL-12 | | rowspan="2" align="left" style="background:#F5F5F5;" + |Anti PL-12 | ||
Line 51: | Line 51: | ||
* Fever, Raynaud's phenomenon, high frequency of ILD | * Fever, Raynaud's phenomenon, high frequency of ILD | ||
* Epstein-Barr virus (EBV), adenovirus, and influenza infection | * Epstein-Barr virus (EBV), adenovirus, and influenza infection | ||
| align="left" style="background:#F5F5F5;" + | | | rowspan="2" align="left" style="background:#F5F5F5;" + |<5% | ||
|- | |- | ||
| align="left" style="background:#F5F5F5;" + |Alanyl-tRNA | | align="left" style="background:#F5F5F5;" + |Alanyl-tRNA | ||
|- | |||
| align="left" style="background:#F5F5F5;" + |Anti-EJ | |||
| align="left" style="background:#F5F5F5;" + |Glycyl-tRNA synthetase | |||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
| align="left" style="background:#F5F5F5;" + |5-10% | |||
|- | |- | ||
| align="left" style="background:#F5F5F5;" + |Anti-OJ | | align="left" style="background:#F5F5F5;" + |Anti-OJ | ||
| align="left" style="background:#F5F5F5;" + |Isoleucyl-tRNA synthetase | | align="left" style="background:#F5F5F5;" + |Isoleucyl-tRNA synthetase | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + |<5% | ||
|- | |- | ||
|Anti-KS | |Anti-KS | ||
|Asparaginyl | |Asparaginyl-tRNA synthetase | ||
| | | | ||
|<5% | |||
|- | |- | ||
|Anti-Ha | |Anti-Ha | ||
|Tyrosyl | |Tyrosyl-tRNA synthetase | ||
| | | | ||
|<1% | |||
|- | |- | ||
|Anti-Zo | |Anti-Zo | ||
| | |Phenylalanyl-tRNA synthetase | ||
| | | | ||
|<1% | |||
|- | |- | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
Line 97: | Line 93: | ||
| align="left" style="background:#F5F5F5;" + |Signal recognition particle | | align="left" style="background:#F5F5F5;" + |Signal recognition particle | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Cardiac involvement | * Cardiac involvement | ||
* Necrotizing myopathy | |||
* Flare up in fall | * Flare up in fall | ||
* Very acute and severe onset | * Very acute and severe onset | ||
Line 103: | Line 100: | ||
* Very poor prognosis | * Very poor prognosis | ||
| align="left" style="background:#F5F5F5;" + |<5% | | align="left" style="background:#F5F5F5;" + |<5% | ||
|- | |- | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
Line 123: | Line 113: | ||
|- | |- | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
| align="left" style="background:#F5F5F5;" + |Anti | | align="left" style="background:#F5F5F5;" + |Anti-MJ | ||
| align="left" style="background:#F5F5F5;" + |Nuclear matrix protein | | align="left" style="background:#F5F5F5;" + |Nuclear matrix protein (NXP-2) | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Cancer-associated myositis | * Cancer-associated myositis | ||
Line 131: | Line 121: | ||
|- | |- | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
| align="left" style="background:#F5F5F5;" + |Anti-SAE | | align="left" style="background:#F5F5F5;" + |Anti-SAE | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + |Small ubiquitin-like modifier activating enzyme | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Cancer-associated myositis | * Cancer-associated myositis | ||
Line 138: | Line 128: | ||
|- | |- | ||
| | | | ||
| | |Anti-caDM-140 | ||
|Intracytoplasmic MDA5 | |Intracytoplasmic MDA5 | ||
| | | | ||
* Dermatomyositis and rapidly progressive ILD | * Dermatomyositis and rapidly progressive ILD | ||
|50% (C-ADM) | |||
|- | |||
| | | | ||
|Anti-PMS1 | |||
|DNA mismatch repair enzyme | |||
| | |||
|7.5% | |||
|- | |- | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
| align="left" style="background:#F5F5F5;" + |Anti HMGCR | | align="left" style="background:#F5F5F5;" + |Anti-HMGCR | ||
| align="left" style="background:#F5F5F5;" + |3-hydroxy-3-methylglutaryl-coenzyme A reductase | | align="left" style="background:#F5F5F5;" + |3-hydroxy-3-methylglutaryl-coenzyme A reductase | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
Line 172: | Line 168: | ||
| | | | ||
| | | | ||
|- | |||
| | |||
|Anti–PM-Scl | |||
| | |||
| | |||
* Overlap of polymyositis and Scleroderma | |||
|25% | |||
|} | |} | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} |
Revision as of 19:08, 12 April 2018
Polymyositis and dermatomyositis Microchapters |
Differentiating Polymyositis and dermatomyositis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Polymyositis and dermatomyositis laboratory findings On the Web |
American Roentgen Ray Society Images of Polymyositis and dermatomyositis laboratory findings |
Polymyositis and dermatomyositis laboratory findings in the news |
Blogs on Polymyositis and dermatomyositis laboratory findings |
Risk calculators and risk factors for Polymyositis and dermatomyositis laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
Laboratory Findings
- Different laboratory tests may be used to diagnose polymyositis and dermatomyositis and exclude other myopathies which include:[1][2][3][4][5][6][7][8]
Sarcoplasmic enzymes
- Sarcoplasmic enzymes consistent with the diagnosis of polymyositis and dermatomyositis include:[11]
- Creatine phosphokinase
- Aldolase
- Transaminases
- Lactic dehydrogenase
Myositis-specific autoantibodies
Autoantibody | Antigen | Features | Frequency | |
---|---|---|---|---|
Antisynthetase | Anti-Jo-1 | Histidyl-tRNA synthetase |
|
20-25% |
Anti-PL-7 | Threonyl-tRNA synthetase |
|
5-10% | |
Anti PL-12 | Alanyl-tRNA synthetase |
|
<5% | |
Alanyl-tRNA | ||||
Anti-EJ | Glycyl-tRNA synthetase | 5-10% | ||
Anti-OJ | Isoleucyl-tRNA synthetase | <5% | ||
Anti-KS | Asparaginyl-tRNA synthetase | <5% | ||
Anti-Ha | Tyrosyl-tRNA synthetase | <1% | ||
Anti-Zo | Phenylalanyl-tRNA synthetase | <1% | ||
Anti Mi-2 | Chromodomain helicase DNA binding protein 4 |
|
5-10% | |
Anti-SRP | Signal recognition particle |
|
<5% | |
Anti-p155/140 | Transcriptional intermediary factor 1-gamma |
|
13-21% in IIM
23-29% in JDM | |
Anti-MJ | Nuclear matrix protein (NXP-2) |
|
23% in JDM | |
Anti-SAE | Small ubiquitin-like modifier activating enzyme |
|
5% | |
Anti-caDM-140 | Intracytoplasmic MDA5 |
|
50% (C-ADM) | |
Anti-PMS1 | DNA mismatch repair enzyme | 7.5% | ||
Anti-HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase |
|
6% | |
Others | Anti-FER | Elongation factor 1 alpha | ||
Anti-KJ | Unidentified cytoplasmic protein | |||
Anti-MAS | Unidentified cytoplasmic RNA | |||
Anti–PM-Scl |
|
25% |
References
- ↑ Adler BL, Christopher-Stine L (February 2018). "Triggers of inflammatory myopathy: insights into pathogenesis". Discov Med. 25 (136): 75–83. PMID 29579414.
- ↑ Bodoki L, Nagy-Vincze M, Griger Z, Betteridge Z, Szöllősi L, Dankó K (December 2014). "Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort". Autoimmun Rev. 13 (12): 1211–9. doi:10.1016/j.autrev.2014.08.011. PMID 25182203.
- ↑ Khan, Sabiha; Christopher-Stine, Lisa (2011). "Polymyositis, Dermatomyositis, and Autoimmune Necrotizing Myopathy: Clinical Features". Rheumatic Disease Clinics of North America. 37 (2): 143–158. doi:10.1016/j.rdc.2011.01.001. ISSN 0889-857X.
- ↑ Dobloug, Cecilie; Garen, Torhild; Bitter, Helle; Stjärne, Johan; Stenseth, Guri; Grøvle, Lars; Sem, Marthe; Gran, Jan Tore; Molberg, Øyvind (2015). "Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort". Annals of the Rheumatic Diseases. 74 (8): 1551–1556. doi:10.1136/annrheumdis-2013-205127. ISSN 0003-4967.
- ↑ Chinoy, H.; Fertig, N.; Oddis, C. V; Ollier, W. E R; Cooper, R. G (2007). "The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis". Annals of the Rheumatic Diseases. 66 (10): 1345–1349. doi:10.1136/ard.2006.068502. ISSN 0003-4967.
- ↑ Dalakas, Marinos C; Hohlfeld, Reinhard (2003). "Polymyositis and dermatomyositis". The Lancet. 362 (9388): 971–982. doi:10.1016/S0140-6736(03)14368-1. ISSN 0140-6736.
- ↑ Douglas, William W.; Tazelaar, Henry D.; Hartman, Thomas E.; Hartman, Robert P.; Decker, Paul A.; Schroeder, Darrell R.; Ryu, Jay H. (2001). "Polymyositis–Dermatomyositis-associated Interstitial Lung Disease". American Journal of Respiratory and Critical Care Medicine. 164 (7): 1182–1185. doi:10.1164/ajrccm.164.7.2103110. ISSN 1073-449X.
- ↑ Miller, Frederick W. (1993). "Myositis-Specific Autoantibodies". JAMA. 270 (15): 1846. doi:10.1001/jama.1993.03510150080034. ISSN 0098-7484.
- ↑ Targoff, Ira N. (2006). "Myositis specific autoantibodies". Current Rheumatology Reports. 8 (3): 196–203. doi:10.1007/s11926-996-0025-3. ISSN 1523-3774.
- ↑ Gunawardena, H.; Betteridge, Z. E.; McHugh, N. J. (2009). "Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression". Rheumatology. 48 (6): 607–612. doi:10.1093/rheumatology/kep078. ISSN 1462-0324.
- ↑ Bohan, Anthony; Peter, James B. (1975). "Polymyositis and Dermatomyositis". New England Journal of Medicine. 292 (8): 403–407. doi:10.1056/NEJM197502202920807. ISSN 0028-4793.